Special Issue

Advances in Bone Metastatic Cancer Research

Message from the Guest Editors

Cancer cells metastasize into bone via a multistep process, and complex interactions between transformed cells and hematopoietic, endothelial, and bone cells occur. Breast and prostate cancer are solid tumors that often metastasize in the bone. In addition, other types of cancer, such as lung carcinoma, also have a high tropism for the bone environment. Cancer cells interact with bone cells either to modulate their dormancy or their drug resistance. Cells of mesenchymal origin, such as osteoblasts and fibroblasts, represent “endosteal niche cells”, which are considered an important component of the metastatic niche. An early diagnosis of bone metastasis represents a crucial test in order to prevent disease progression. It has been reported that protein or gene expression profiles analyzed in primary tumors as well as circulating DNA or RNA markers associated with tumor cells may predict the tropism and the ability of cancer cells to metastasize in bone. This Special Issue will focus on the mechanisms and pathways involved in the formation of bone metastases and on the possible identification of therapeutic approaches to counteract the onset of bone metastases.

Guest Editors

Dr. Maria Teresa Valenti

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37128 Verona, Italy

Dr. Luca G. Dalle Carbonare

Department of Medicine, University of Verona, Verona, Italy

Deadline for manuscript submissions

closed (31 March 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/126365

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)